reports
Agios Pharmaceuticals Inc: 1 director
A director at Agios Pharmaceuticals Inc sold 772 shares at 56.090USD and the significance rating of the trade was 51/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years ...
Agios to Present New Data on Mitapivat and Tebapivat in Rare Blood Dis...
Agios to Present New Data on Mitapivat and Tebapivat in Rare Blood Disorders at 66th ASH Annual Meeting and Exposition – Results from Phase 3 ENERGIZE-T Study of Mitapivat in Transfusion-dependent Thalassemia will be Presented in Oral Session – – Tebapivat Phase 1 Data in Sickle Cell Disease and Phase 2b Trial-in-progress Update in Lower-risk Myelodysplastic Syndromes will be Presented and Published – – Live and Webcast Investor Event with Agios Leadership and Medical Experts will be Hosted Onsite on Monday, December 9 – CAMBRIDGE, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Agios P...
Agios Reports Business Highlights and Third Quarter 2024 Financial Res...
Agios Reports Business Highlights and Third Quarter 2024 Financial Results – Completed Enrollment of the Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease; Topline Data from 52-Week Study Expected in Late 2025 – – Received $1.1 Billion in Payments from Royalty Pharma and Servier, Following FDA Approval of Vorasidenib – – Commenced Enrollment of the Phase 2b Study of Tebapivat in Lower-Risk Myelodysplastic Syndromes (LR-MDS); Granted FDA Orphan Drug Designation for Treatment of MDS – – PYRUKYND® (Mitapivat) Net Revenue of $9.0 Million in Q3; Cash, Cash Equivalents and Marketable S...
Agios Completes Enrollment of Phase 3 RISE UP Study of Mitapivat in Si...
Agios Completes Enrollment of Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease – Topline Data from 52-week Phase 3 Study Expected in Late 2025 – CAMBRIDGE, Mass., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today announced that enrollment is complete for the Phase 3 RISE UP study. This global, double-blind, randomized, placebo-controlled trial is evaluating the efficacy and safety of mitapivat, an oral, small molecule PK activator, in sick...
Agios to Webcast Conference Call of Third Quarter 2024 Financial Resul...
Agios to Webcast Conference Call of Third Quarter 2024 Financial Results on October 31, 2024 CAMBRIDGE, Mass., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced the company will host a conference call and live webcast on Thursday, October 31, 2024, at 8:00 a.m. ET to report its third quarter 2024 financial results and business highlights. A live webcast of the presentation can be accessed under "Events & Presentations" in the Investors section of the compa...
Agios Announces FDA Orphan Drug Designation Granted to Tebapivat (AG-9...
Agios Announces FDA Orphan Drug Designation Granted to Tebapivat (AG-946) for Treatment of Myelodysplastic Syndromes (MDS) CAMBRIDGE, Mass., Sept. 11, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the company’s novel pyruvate kinase (PK) activator tebapivat (AG-946) for the treatment of myelodysplastic syndromes (MDS). “Receiving orphan drug designation for tebapivat in ...
Agios to Present at the 2024 Cantor Global Healthcare Conference on Se...
Agios to Present at the 2024 Cantor Global Healthcare Conference on September 18, 2024 CAMBRIDGE, Mass., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that the company is scheduled to present at the 2024 Cantor Global Healthcare Conference on Wednesday, September 18, 2024, at 10:20 a.m. ET. A live webcast of the presentation can be accessed under "Events & Presentations" in the Investors section of the company's website at . A replay of the webcast wi...
Agios to Receive $1.1 Billion in Milestone Payments Following FDA Appr...
Agios to Receive $1.1 Billion in Milestone Payments Following FDA Approval of Vorasidenib – Agios Expects to Receive $905 Million Payment from Royalty Pharma and $200 Million Payment from Servier in Q3 2024; Payments Increase Agios’ Pro-Forma Cash Position as of June 30, 2024, to $1.7 Billion – – Strong Cash Position to Enable Agios to Prepare for Potential PYRUKYND® (Mitapivat) Launches in Thalassemia in 2025 and Sickle Cell Disease in 2026 and Drive Pipeline Progress – CAMBRIDGE, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular ...
Agios Reports Business Highlights and Second Quarter 2024 Financial Re...
Agios Reports Business Highlights and Second Quarter 2024 Financial Results – Reported Positive Topline Data from Phase 3 ENERGIZE-T Study; Expect to File sNDA Based on ENERGIZE and ENERGIZE-T Studies Encompassing All Thalassemia Subtypes by End of 2024 – – Announced $905 Million Purchase Agreement for Vorasidenib Royalty with Royalty Pharma; Agios to Receive a Total of $1.1 Billion in Payments Upon FDA Approval of Vorasidenib – – Reported Results from Phase 3 ACTIVATE-KidsT Study of Mitapivat in Children with Pyruvate Kinase (PK) Deficiency Who are Regularly Transfused – – PYRUKYND® (Mi...
Agios Announces Results from Phase 3 ACTIVATE-KidsT Study of Mitapivat...
Agios Announces Results from Phase 3 ACTIVATE-KidsT Study of Mitapivat in Children with PK Deficiency Who Are Regularly Transfused – ACTIVATE-KidsT is Agios’ First Pediatric Data Readout;Safety Results Consistent with Safety Profile for Mitapivat Previously Observed in Adultswith PK Deficiency Who are Regularly Transfused – – Prespecified Statistical Criterion for the Primary Endpoint in ACTIVATE-KidsT Was Not Met; Results Were Clinically Meaningful, with Observed Response Rates Higher for Mitapivat than Placebo for the Primary Endpoint of Transfusion Reduction Response and for the Seconda...
Agios to Webcast Conference Call of Second Quarter 2024 Financial Resu...
Agios to Webcast Conference Call of Second Quarter 2024 Financial Results on August 1, 2024 CAMBRIDGE, Mass., July 18, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced the company will host a conference call and live webcast on Thursday, August 1, 2024, at 8:00 a.m. ET to report its second quarter 2024 financial results and other business highlights. A live webcast of the presentation can be accessed under "Events & Presentations" in the Investors section of the c...
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
SRPT SAREPTA THERAPEUTICS INC.
SPR SPIRIT AEROSYSTEMS HOLDINGS INC. CLASS A
MNKD MANNKIND CORP.
BCRX BIOCRYST PHARMACEUTICALS INC.
ALNY ALNYLAM PHARMACEUTICALS INC
AGIO AGIOS PHARMACEUTICALS INC.
RY4C RYANAIR HOLDINGS PLC
LILA LIBERTY LATIN AMERICA A
DNLI DENALI THERAPEUTICS INC
ADT ADT INC
HROW HARROW HEALTH INC.
TWST TWIST BIOSCIENCE
DYN DYNE THERAPEUTICS
SMLP SUMMIT MIDSTREAM PARTNERS
RNA AVIDITY BIOSCIENCES
TNGX TANGO THERAPEUTICS INC
RYAN RYAN SPECIALTY GROUP HLDGS INC
RKLB ROCKET LAB USA INC
BTMD HAYMAKER ACQUISITION CORP III
IBRX IMMUNITYBIO INC
CDRO CODERE ONLINE LUXEMBOURG SA
XPOF XPONENTIAL FITNESS INC
UBXG U BX TECHNOLOGY LTD
FTLF FITLIFE BRANDS INC.
Agios Presents Positive Results from Phase 3 ENERGIZE Study of Mitapiv...
Agios Presents Positive Results from Phase 3 ENERGIZE Study of Mitapivat in Non-Transfusion-Dependent Thalassemia in Plenary Session at the European Hematology Association 2024 Hybrid Congress – ENERGIZE is the First Study to Demonstrate Efficacy of an Oral Treatment for Non-Transfusion-Dependent Alpha- and Beta-Thalassemia – – Additional ENERGIZE Poster Presentation Highlights Improvements in Fatigue and Exercise Capacity in Patients Treated with Mitapivat Compared to Placebo – – Agios to Webcast Virtual Investor Event on June 16, 2024 at 10 a.m. Eastern Time or 4 p.m. Central European S...
Updated Time: Agios to Present at the Goldman Sachs 45th Annual Global...
Updated Time: Agios to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024 at 8:40 am ET CAMBRIDGE, Mass., June 06, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that the time of the company’s presentation at the Goldman Sachs 45th Annual Global Healthcare Conference has been updated to Monday, June 10, 2024 at 8:40 a.m. ET. A live webcast of the presentation can be accessed under "Events & Presentations" in the Investors sect...
Agios Announces Phase 3 ENERGIZE-T Study of Mitapivat Met Primary Endp...
Agios Announces Phase 3 ENERGIZE-T Study of Mitapivat Met Primary Endpoint and All Key Secondary Endpoints in Adults with Transfusion-Dependent Alpha- or Beta-Thalassemia – Study Achieved the Primary Endpoint; Mitapivat Demonstrated a Statistically Significant Transfusion Reduction Response Compared to Placebo – – Statistical Significance Achieved for All Key Secondary Endpoints Evaluating Additional Measures of Reduction of Transfusion Burden Compared to Placebo – – ENERGIZE-T is the First Phase 3 Study to Demonstrate Efficacy of an Oral, Disease-Modifying Treatment for Transfusion-Depe...
Agios to Present at the Goldman Sachs 45th Annual Global Healthcare Co...
Agios to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024 CAMBRIDGE, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that the company is scheduled to present at the Goldman Sachs 45th Annual Global Healthcare Conference on Monday, June 10, 2024, at 1:20 p.m. ET. A live webcast of the presentation can be accessed under "Events & Presentations" in the Investors section of the company's website at . A replay of th...
Agios Announces $905 Million Purchase Agreement for Vorasidenib Royalt...
Agios Announces $905 Million Purchase Agreement for Vorasidenib Royalty – Royalty Pharma to Acquire Rights to Agios’ 15% Royalty on Potential Vorasidenib U.S. Net Sales for $905 Million Upfront upon FDA Approval of Vorasidenib; Agios to Share in Economics Above Certain Revenue Thresholds – – Agios Retains Rights to $200 Million Milestone Payment from Servier upon FDA Approval of Vorasidenib – – In Total, Agios to Receive $1.1 Billion in Payments upon FDA Approval of Vorasidenib; PDUFA Action Date of August 20, 2024 – CAMBRIDGE, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceutic...
Agios Pharmaceuticals to Present Clinical and Translational Data in Ra...
Agios Pharmaceuticals to Present Clinical and Translational Data in Rare Blood Disorders at European Hematology Association 2024 Hybrid Congress – Data from Phase 3 ENERGIZE Study of Mitapivat in Non-Transfusion-Dependent Thalassemia to be Presented in Plenary Session – – Additional Presentations to Highlight Quality of Life Data from ENERGIZE and Design of the Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease – – Agios to Webcast Virtual Investor Event on June 16, 2024, at 10 a.m. Eastern Time or 4 p.m. Central European Summer Time – CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSW...
Agios to Present at the BofA Securities 2024 Health Care Conference on...
Agios to Present at the BofA Securities 2024 Health Care Conference on May 16, 2024 CAMBRIDGE, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that the company is scheduled to present at the BofA Securities 2024 Health Care Conference on Thursday, May 16, 2024, at 11:40 a.m. ET. A live webcast of the presentation can be accessed under "Events & Presentations" in the Investors section of the company's website at . A replay of the webcast will be arc...
Agios to Present at the RBC Capital Markets Global Healthcare Conferen...
Agios to Present at the RBC Capital Markets Global Healthcare Conference on May 14, 2024 CAMBRIDGE, Mass., May 03, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that the company is scheduled to present at the 2024 RBC Capital Markets Global Healthcare Conference on Tuesday, May 14, 2024, at 8:00 a.m. ET. A live webcast of the presentation can be accessed under "Events & Presentations" in the Investors section of the company's website at . A replay of the webcas...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.